Quarterly Results Overview: Fennec Pharmaceuticals reported revenues of US$9.7m but faced significant losses of US$0.11 per share, leading analysts to revise their earnings forecasts downward for 2025, despite expectations of a revenue increase to US$47.1m.
Analyst Sentiment and Future Growth: The consensus price target remains at US$14.00, indicating stable confidence among analysts, while the company is projected to grow faster than the industry with a forecasted 100% annualized revenue growth by 2025, despite concerns over reduced earnings per share estimates.
FENC
$7.62+Infinity%1D
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.960
Low
13.00
Averages
13.00
High
13.00
Current: 7.960
Low
13.00
Averages
13.00
High
13.00
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$13 -> $14
2025-08-15
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$13 -> $14
2025-08-15
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Fennec to $14 from $13 and keeps a Buy rating on the shares following quarterly results. The firm notes that legal expenses and one-time PSUs tied to 2025 goals drove elevated opex, but management expects material expense reduction in the second half of the year. Growth in the AYA population for Pedmark drove account expansion, with 14 new accounts added in the quarter. Internationally, Pedmarqsi launched in Germany and the U.K., with early royalty contributions from Norgine expected to ramp through the year. Additional EU launches are planned for the first half of 2026, and Japan data expected in Q4 bring potential partnership discussions for Japan rights and non-dilutive capital, Craig-Hallum adds.
Craig-Hallum
Buy
maintain
$12 -> $13
2025-05-14
Reason
Craig-Hallum
Price Target
$12 -> $13
2025-05-14
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Fennec to $13 from $12 and keeps a Buy rating on the shares following the company's Q1 earnings beat. The results for Q1 are near the breakeven amount for revenue, the firm notes. Craig-Hallum says that continued wins at potential major accounts, along with improved adherence to treatment from investments in the commercial team, could start to inflect the AYA channel.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$13
2025-03-11
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$13
2025-03-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$13
2024-12-17
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$13
2024-12-17
Reiterates
Strong Buy
Reason
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
